Nevertheless, targeted blockade of the IRF2 (Type II interferon regulatory factor), enriched for Type II interferons such as IFN-γ suppressor and Kras (classic sarcoma gene), in combination with anti-PD1, significantly reduced CXCL3-CXCR2 levels and MDSC enrichment in various CRC tumor types, resulting in notable tumor suppression. This evidence concerns the gene CXCR2 and neoplasm.